Halozyme Therapeutics, Inc. (HALO) Stock Analysis
Price: $112.60 · -2.20%
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy16 analystsWhat's happening with HALO
Price History
5-Year Weekly Candlestick Chart
Insider Transactions
Recent SEC Form 4 filings
- SellOpen market sale · filed 2026-08-11-1626 sh2026-08-10
- SellOption exercise · filed 2026-07-09-1923 sh2026-07-08
- SellOpen market sale · filed 2026-07-09-1035 sh2026-07-08
- SellOpen market sale · filed 2026-07-09-888 sh2026-07-08
- BuyOption exercise · filed 2026-07-09+1.9K sh2026-07-08
+3 more recent filings
Key Insights: Halozyme Therapeutics, Inc. (HALO)
HALO is down 2.20% in after-hours trading.
- Return on equity of 180.6% is well above the market average.
See how HALO ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all HALO moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 22 | After-hours | 115.69 | +3.80% | 2.73 |
Frequently Asked Questions about HALO
What is the current Halozyme Therapeutics, Inc. (HALO) stock price?
HALO is trading at $112.60 in after-hours trading, down 2.20% on the session. PreMarketPrice tracks HALO pre-market, intraday and after-hours prices.
Is HALO stock overvalued?
Halozyme Therapeutics, Inc. trades at a trailing P/E of 39.8. See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Halozyme Therapeutics, Inc. report earnings?
No confirmed earnings date is currently scheduled for HALO. The Earnings section lists recent reports and updates as dates are announced.
What sector does Halozyme Therapeutics, Inc. operate in?
Halozyme Therapeutics, Inc. operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
About Halozyme Therapeutics, Inc. (HALO) Stock
Halozyme Therapeutics, Inc. (HALO) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. As of the latest update, Halozyme Therapeutics, Inc. is trading at $112.60, down 2.20% on the day with a market capitalization of $12.8 billion. The financial health score for HALO has not yet been calculated — analysis data is being compiled. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for HALO stock.
HALO Stock Analysis & Key Metrics
On PreMarketPrice, you can track Halozyme Therapeutics, Inc. (HALO) across multiple dimensions:
- Pre-market price & movement: Real-time HALO stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Financial health score: A composite score based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for HALO.
- Sector peers: Compare HALO against 10 other healthcare stocks on key financial metrics.
Is HALO a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Halozyme Therapeutics, Inc. (HALO) as an investment. The financial health score is being calculated.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Halozyme Therapeutics, Inc. (HALO) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.